How India Exports Amoxicillin to the World

In the United States, amoxicillin is approved through Abbreviated New Drug Applications (ANDAs), as listed in the FDA's Orange Book. The FDA maintains import alerts to ensure compliance with regulatory standards. For instance, Import Alert 66-66, updated in October 2024, addresses APIs that appear misbranded due to labeling issues. Additionally, Import Alert 16-124, revised in March 2026, pertains to aquaculture seafood products containing unapproved drugs. These alerts underscore the FDA's commitment to safeguarding public health by monitoring imported pharmaceuticals.

In the European Union, the European Medicines Agency (EMA) oversees the marketing authorization of medicinal products, including amoxicillin. The EMA has conducted referrals to harmonize the authorization of amoxicillin-containing products across member states. For example, the Amoxil referral aimed to resolve divergent national decisions regarding amoxicillin products. (ema.europa.eu) Similarly, the Synulox Lactating Cow referral addressed differences in the authorization of veterinary products containing amoxicillin. (ema.europa.eu) These actions reflect the EMA's role in ensuring consistent regulatory standards for antibiotics within the EU.

Amoxicillin is included in the World Health Organization's (WHO) Model List of Essential Medicines, highlighting its importance in global health. The WHO Prequalification Programme ensures that medicines like amoxicillin meet global standards for quality, safety, and efficacy. Additionally, amoxicillin is standardized in various pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality across different regions.

In India, amoxicillin is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines, including amoxicillin, to ensure affordability. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of pharmaceuticals, ensuring compliance with national regulations.

The primary patents for amoxicillin have expired, allowing for generic competition. This has led to a competitive market with multiple manufacturers producing generic versions, contributing to the widespread availability and affordability of amoxicillin globally.

In December 2025, the FDA approved Augmentin XR (amoxicillin-clavulanate potassium) under the Commissioner's National Priority Voucher (CNPV) pilot program, marking the first approval through this expedited review pathway. This approval, completed in two months, aims to strengthen domestic antibiotic manufacturing capacity.

In March 2026, the FDA issued Import Alert 16-124, detaining without physical examination aquaculture seafood products due to unapproved drugs. This alert underscores the FDA's vigilance in monitoring imported products for compliance with U.S. regulations.

These developments reflect ongoing efforts by regulatory authorities to ensure the quality and safety of pharmaceuticals and related products in the market.

Amoxicillin, a widely used antibiotic, relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) for its production. India, a major exporter of amoxicillin, sources a significant portion of these critical components from China. According to the US Pharmacopeia, 41% of KSMs used for U.S.-approved APIs are solely sourced from China, highlighting a substantial dependency.

This reliance poses a risk to the supply chain, as any disruption in Chinese exports—due to geopolitical tensions, trade restrictions, or other factors—could impact the availability of amoxicillin APIs in India. Such disruptions have occurred in the past, emphasizing the need for diversified sourcing strategies to ensure a stable supply chain.

Our proprietary trade data indicates that the top five Indian exporters account for 63.2% of amoxicillin exports, with MICRO LABS LIMITED alone contributing 26.5% ($161.8 million). This high concentration among a few suppliers increases the risk of supply chain disruptions if any of these key players face operational challenges.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) Scheme for Pharmaceuticals, aiming to boost domestic manufacturing of critical APIs and reduce import dependence. As of December 2025, the scheme has led to the creation of manufacturing capacities for 26 KSMs/APIs, resulting in cumulative sales of ₹2,315 crore and avoiding imports worth ₹1,807 crore.

Global shipping routes, including the Red Sea and the Strait of Hormuz, are susceptible to geopolitical tensions that can disrupt maritime transport. Such disruptions can delay the delivery of raw materials and finished pharmaceutical products, impacting the amoxicillin supply chain.

Additionally, ongoing U.S.-China trade tensions have led to increased scrutiny and potential restrictions on pharmaceutical imports and exports. These geopolitical factors necessitate proactive risk management strategies to ensure uninterrupted supply chains.

• Diversify Sourcing: Identify and qualify alternative suppliers for APIs and KSMs to reduce dependency on a single country or supplier.

• Enhance Domestic Production: Leverage government incentives, such as the PLI Scheme, to invest in local manufacturing capabilities for critical pharmaceutical components.

• Strengthen Supplier Relationships: Develop strategic partnerships with key suppliers to ensure priority access during supply disruptions.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events and assess their potential impact on the supply chain.

• Implement Supply Chain Resilience Plans: Develop and regularly update contingency plans to address potential disruptions in the supply chain.

RISK_LEVEL: MEDIUM